We aspire to have the greatest impact on patients and science of any biotechnology company in the history of our industry. To us, that means creating novel medicines that benefit individuals and society, and bringing new scientific understanding to diseases for which there are no adequate treatments.

Patient services

Financial assistance

Patient safety

Dedicated to new discoveries

Our pipeline is more than a list of medicines in development. It reflects the work we do here every day to break new ground with science that makes a difference in the lives of patients.

Filter By:

All disease areas

All disease areas

Alzheimer's Disease

Fibrosis

Inflammatory Bowel Disease (IBD)

Lupus

Lymphoma

Multiple Sclerosis (MS)

Myotonic Dystrophy

Ophthalmology

Parkinson's Disease

Sjögren's Syndrome

Spinal Muscular Atrophy (SMA)

Stroke

Trigeminal Neuralgia

All phases

All phases

Filed

Phase 3

Phase 2

Phase 1

Phase

01Phase 1

02Phase 2

03Phase 3

Filed

Aducanumab (Aβ mAb)

Alzheimer’s disease

Developed in collaboration with Neurimmune.

Alzheimer’s disease (AD) is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability. It is estimated that more than 25 million individuals are living with AD worldwide1.

Today we understand that AD is a continuum with a long silent phase that begins years before symptoms appear. As AD progresses, symptoms like memory loss, personality and behavioral changes commonly associated with AD begin to manifest.

How this therapy could help:
The memory loss and functional decline of Alzheimer’s disease have been linked to amyloid plaques, abnormal protein deposits that build up in the brain. Aducanumab is an antibody that binds to and may reduce amyloid plaques from the brain, potentially slowing the progress of the disease.

This disease causes the body’s immune system to attack myelin, a protective sheath covering nerve fibers. Damage to myelin “short circuits” communication between the brain, spinal cord and other areas of the body, severely impairing such neurological functions as mobility, vision and thinking. Over time, the nerves themselves can become damaged permanently.

How this therapy could help:

BIIB098 (monomethyl fumarate prodrug) is a monomethyl fumarate (MMF) prodrug investigational candidate designed to rapidly and efficiently convert to MMF in the body and may offer differentiated features as compared to the currently marketed dimethyl fumarate.

E2609 (BACE1 inhibitor)

Alzheimer's disease

Developed in collaboration with Eisai Co., Ltd.

Alzheimer’s disease (AD) is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability. It is estimated that more than 25 million individuals are living with AD worldwide1.

Today we understand that AD is a continuum with a long silent phase that begins years before symptoms appear. As AD progresses, symptoms like memory loss, personality and behavioral changes commonly associated with AD begin to manifest.

How this therapy could help:
The memory loss and functionality decline of Alzheimer’s disease have been linked to amyloid plaques, abnormal protein deposits that build up in the brain. E2609 is a small-molecule inhibitor of beta-secretase, a protein that cleaves enzyme 1 (BACE1). By inhibiting BACE1, E2609 blocks amyloid production, potentially slowing the progress of the disease.

Alzheimer’s disease (AD) is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability. It is estimated that more than 25 million individuals are living with AD worldwide1.

Today we understand that AD is a continuum with a long silent phase that begins years before symptoms appear. As AD progresses, symptoms like memory loss, personality and behavioral changes commonly associated with AD begin to manifest.

How this therapy could help:
The memory loss and functionality decline of Alzheimer’s disease have been linked to amyloid plaques, abnormal protein deposits that build up in the brain. BAN2401 is an antibody that binds to amyloid, which could reduce its presence in the brain and potentially slow the progress of the disease.

Pulmonary fibrosis is a disease in which lung tissue becomes thickened and stiff due to scarring. The formation of scar tissue is called fibrosis. As the disease progresses, it becomes harder for the lungs to work properly and the body cannot get the oxygen it needs. This debilitating disease is almost always fatal.

How this therapy could help:
The TGF-beta brain cell pathway is involved in several fibrotic diseases. The BG00011 (STX-100) antibody may selectively block the TGF-beta pathway, and may slow the development of fibrosis in IPF patients.

BIIB054 (anti-α-synuclein)

Parkinson's disease

Acquired from Neurimmune.

Parkinson's disease is a disorder of the central nervous system. People who have this disease experience tremors, slow movement, muscle stiffness, and impaired balance. As these symptoms become progressively worse, patients have difficulty walking, talking, or completing other simple tasks.

How this therapy could help:
BIIB054 targets abnormal alpha-synuclein protein that is associated with the destruction of nerve cells. This progressive degeneration is the cause of Parkinson's disease.

BIIB059 (anti-BDCA2)

Lupus

This chronic inflammatory disease occurs when the body’s own immune system mistakenly attacks healthy tissue in skin, joints, kidneys, the brain and other organs. It is a difficult disease to diagnose because it resembles several other conditions.

How this therapy could help:
BDCA2 is a protein present in specific cells within the immune system. An antibody against BDCA2 can potentially interrupt production of interferons, inflammatory molecules that are increased in patients with lupus and contribute to disease activity.

BIIB074 (vixotrigine)

Trigeminal neuralgia (TGN)

Acquired in acquisition of Convergence Pharmaceuticals

Trigeminal neuralgia is an extremely painful condition usually involving one side of the face. Trigeminal neuralgia is characterized by sudden, brief, stabbing, recurrent episodes of pain which frequently occurs spontaneously but is also commonly evoked by trivial stimuli including washing, shaving, smoking, talking and/or brushing the teeth (trigger factors). The pain follows one or more branches of the trigeminal nerve, which provides nerve sensation from the mouth, face and the front of the scalp. The intensity of the pain and its unpredictability results in profound effects on the quality of life of patients.

How this therapy could help:
BIIB074 (vixotrigine) is a novel state dependent small molecule sodium channel blocker that preferentially inhibits the Nav 1.7 ion channel, a therapeutic target implicated by genetics in human pain conditions. BIIB074 is thought to penetrate the central nervous system and block Nav channels in a novel manner, and has the potential to provide a new and effective option for the treatment of trigeminal neuralgia.

BIIB093 (glibenclamide IV)

Stroke

It is estimated that nearly two million people in the United States and the European Union will have a stroke each year. Stroke is a leading cause of mortality and serious long-term disability. There is a substantial unmet medical need for new therapies that can improve outcomes in acute stroke. The target indication for BIIB093 (glibenclamide IV) is large hemispheric infarction (LHI), a severe form of ischemic stroke where brain swelling (cerebral edema) often leads to a disproportionately large share of stroke-related morbidity and mortality.

How this therapy could help:
In pre-clinical studies, BIIB093 (glibenclamide IV) has been shown to block SUR1-TRPM4 channels that mediate stroke related brain swelling. Clinical proof-of-concept studies have demonstrated the potential of BIIB093 to reduce brain swelling, disability and the risk of death in patients with LHI.

Dapirolizumab pegol (anti-CD40L)

Lupus

Developed in collaboration with UCB, Inc.

This chronic inflammatory disease occurs when the body’s own immune system mistakenly attacks healthy tissue in skin, joints, kidneys, the brain and other organs. It is a difficult disease to diagnose because it resembles several other conditions.

How this therapy could help:
CD40L is a protein in B and T cells, which helps regulate the immune system. Dapirolizumab pegol (anti-CD40L) is an antibody that blocks CD40L, potentially lessening disease activity in lupus patients.

Opicinumab (anti-LINGO)

Multiple sclerosis (MS)

This disease causes the body’s immune system to attack myelin, a protective sheath covering nerve fibers. Damage to myelin “short circuits” communication between the brain, spinal cord and other areas of the body, severely impairing such neurological functions as mobility, vision and thinking. Over time, the nerves themselves can become damaged permanently.

How this therapy could help:
LINGO-1 is a CNS specific-protein that is involved in the development of myelin. In patients with MS, LINGO-1 may inhibit myelin growth when it binds with its receptor. Data suggest that the antibody anti-LINGO-1 could block this process, potentially allowing for the re-myelination and restoration of nerve communication in MS patients.

XLRS Gene Therapy

X-linked retinoschisis (XLRS)

Developed in collaboration with AGTC

XLRS is a disease that affects young males beginning in their teenage years. It can lead to loss of vision and serious complications such as vitreous hemorrhage or retinal detachment during adulthood.

Alzheimer’s disease (AD) is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability. It is estimated that more than 25 million individuals are living with AD worldwide1.

Today we understand that AD is a continuum with a long silent phase that begins years before symptoms appear. As AD progresses, symptoms like memory loss, personality and behavioral changes commonly associated with AD begin to manifest.

How this therapy could help:
The memory loss and functional decline of AD have been linked to abnormal protein deposits that build up in the brain. Among those proteins are amyloid and tau. Deposits of abnormal tau, so-called neurofibrillary tangles, form in the neurons and are linked to increasing impairment and loss of brain cells associated both with AD and with other neurodegenerative diseases, known as tauopathies, such as progressive supranuclear palsy and frontotemporal dementia. BIIB076 is an antibody targeting tau, the protein that forms the deposits, or tangles, in the brain.

Alzheimer’s disease (AD) is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability. It is estimated that more than 25 million individuals are living with AD worldwide1. Today we understand that AD is a continuum with a long silent phase that begins years before symptoms appear. As AD progresses, symptoms like memory loss, personality and behavioral changes commonly associated with AD begin to manifest.

How this therapy could help:The memory loss and functional decline of Alzheimer’s disease have been linked to amyloid plaques and tau tangles, abnormal protein deposits that build up in the brain and in the brain cells. BIIB080 (IONIS-MAPTRx) is an antisense oligonucleotide (ASO) that may reduce production of the tau protein and its accumulation in brain cells, potentially slowing the progress of the disease.

Alzheimer’s disease (AD) is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability. It is estimated that more than 25 million individuals are living with AD worldwide1.

Today we understand that AD is a continuum with a long silent phase that begins years before symptoms appear. As AD progresses, symptoms like memory loss, personality and behavioral changes commonly associated with AD begin to manifest.

How this therapy could help:
The memory loss and functional decline of AD have been linked to abnormal protein deposits that build up in the brain. Among those proteins are amyloid and tau. Deposits of abnormal tau, so-called neurofibrillary tangles, form in the neurons and are linked to increasing impairment and loss of brain cells associated both with AD and with other neurodegenerative diseases, known as tauopathies, such as progressive supranuclear palsy and frontotemporal dementia. BIIB092 is an antibody targeting extracellular tau and may reduce the spreading of tau from one cell to the next, potentially slowing the progress of the disease.

Important Notice:

You are now leaving Biogen’s corporate website.
We encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from Biogen’s standards.

Third Party Sites
Biogen assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site's endorsement of Biogen or this website.